Open Orphan plc, a rapidly growing specialist pharmaceutical services contract research organisation and world leader in vaccine and antiviral testing using human challenge clinical trials, announces that hVIVO, a subsidiary of Open Orphan plc, has signed a contract with Imperial College London, as part of a Wellcome Trust funded initiative to manufacture a SARS-CoV-2 challenge virus.
May 10, 2021
· 6 min read